annotating cancer variants and anti-cancer therapeutics in reactome注释在reactome癌症变异和抗癌疗法.pdfVIP

Cancers 2012, 4, 1180-1211; doi:10.3390/cancers4041180 OPEN ACCESS OPEN ACCESS cancers ISSN 2072-6694 /journal/cancers Article Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome Marija Milacic 1, Robin Haw 1,*, Karen Rothfels 1, Guanming Wu 1, David Croft 2, Henning Hermjakob 2, Peter D’Eustachio 3 and Lincoln Stein 1 1 Informatics and Bio-computing Platform, Ontario Institute for Cancer Research, Toronto, ON, M5G0A3, Canada; E-Mails: MOrlic-Milacic@oicr.on.ca (M.M.); Karen.Rothfels@oicr.on.ca (K.R.); guanmingwu@ (G.W.); lincoln.stein@ (L.S.) 2 European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK; E-Mails: croft@ebi.ac.uk (D.C.); hhe@ebi.ac.uk (H.H.) 3 Department of Biochemistry, NYU School of Medicine, New York, NY 10016, USA; E-Mail: Peter.D’Eustachio@ * Author to whom correspondence should be addressed; E-Mail: robin.haw@oicr.on.ca; Tel.: +1-647-260-7985; Fax: +1-416-977-1118. Received: 8 October 2012; in revised form: 31 October 2012 / Accepted: 2 November 2012 / Published: 8 November 2012 Abstract: Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications to accommodate annotation of changes in amino acid sequence and the formation of fusion proteins to describe the proteins involved in disease processes. Second